For the updated versions of the Summary of Product Characteristics (SmPC) and the Patient Information Leaflet (PIL), please refer to the EMA (European Medicines Agency) website.
In accordance with the current legislation, we are unable to provide any information about our drugs concerning health issues. Anyone requiring these details should contact their treating physician.
Disclaimer: Only available in the Netherlands
For the updated versions of the Summary of Product Characteristics (SmPC) and the Patient Information Leaflet (PIL), please refer to the EMA (European Medicines Agency) website.
In accordance with the current legislation, we are unable to provide any information about our drugs concerning health issues. Anyone requiring these details should contact their treating physician.
Disclaimer: Only available in the Netherlands
For the updated versions of the Summary of Product Characteristics (SmPC) and the Patient Information Leaflet (PIL), please refer to the EMA (European Medicines Agency) website.
In accordance with the current legislation, we are unable to provide any information about our drugs concerning health issues. Anyone requiring these details should contact their treating physician.
For the updated versions of the Summary of Product Characteristics (SmPC) and the Patient Information Leaflet (PIL), please refer to the EMA (European Medicines Agency) website.
In accordance with the current legislation, we are unable to provide any information about our drugs concerning health issues. If you have any questions about this product or your health, please contact your physician.
Disclaimer: Ferriprox 1000 mg tablets only available in The Netherlands.
For the updated versions of the Summary of Product Characteristics (SmPC) and the Patient Information Leaflet (PIL), please refer to the EMA (European Medicines Agency) website.
In accordance with the current legislation, we are unable to provide any information about our drugs concerning health issues. Anyone requiring these details should contact their treating physician.
Insert text here...
For the updated versions of the Summary of Product Characteristics (SmPC) and the Patient Information Leaflet (PIL), please refer to the EMA (European Medicines Agency) website.
In accordance with the current legislation, we are unable to provide any information about our drugs concerning health issues. Anyone requiring these details should contact their treating physician.
For the updated versions of the Summary of Product Characteristics (SmPC) and the Patient Information Leaflet (PIL), please refer to the EMA (European Medicines Agency) website.
In accordance with the current legislation, we are unable to provide any information about our drugs concerning health issues. Anyone requiring these details should contact their treating physician.
Learn More about Chiesi Global Rare Diseases - Benelux
In
the News
Stay up to date with the latest news and happenings at Chiesi Global Rare Diseases - Benelux.
Pipeline
Explore rare disease therapies under development.
About
Us
Learn more about who we are and why Chiesi Global Rare Disease - Benelux cares about improving the lives of people with rare diseases.
For Healthcare
Professionals
From research to results, see how we’re committed to helping you help your patients.